Clinical Scorecard: Comparative Survival Rates in Advanced Gastric Cancer with Low ERBB2 Expression versus ERBB2 Null Status

At a Glance

Key Highlights

• Gastric cancer is the fifth most commonly diagnosed cancer worldwide.
• ERBB2 positivity is defined by specific immunohistochemistry scores.
• Trastuzumab improves outcomes in ERBB2-positive advanced gastric cancer.
• ERBB2-low expression has uncertain prognostic impact.
• The study compares clinicopathologic features of ERBB2-low and ERBB2-null gastric cancer.

Guideline-Based Recommendations

Diagnosis

• ERBB2 assessment is performed using immunohistochemistry (IHC) and in situ hybridization (ISH) for equivocal cases.

Management

• Trastuzumab is used in combination with chemotherapy for ERBB2-positive cases.

Monitoring & Follow-up

• Progression-free survival (PFS) and overall survival (OS) are primary outcomes for monitoring.

Risks

• Patients with ERBB2-low expression have historically been managed similarly to ERBB2-null disease.

Patient & Prescribing Data

Patients aged 18 years or older with pathologically confirmed ERBB2-null or ERBB2-low metastatic gastric cancer.

Treatment modalities include chemotherapy, immunotherapy, and targeted therapy.

Clinical Best Practices

• Accurate ERBB2 assessment is critical for guiding treatment decisions.
• Consideration of demographic characteristics in treatment outcomes is important.

Related Resources & Content

• Gastric Cancer Statistics
• Trastuzumab for Gastric Cancer (ToGA) Trial
• STROBE Reporting Guidelines